Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan

Aptose Biosciences Inc.

Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.
Facility funds clinical development of Tuspetinib for AML triplet therapy.
Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.
Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship.

item 1.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.